Zobrazeno 1 - 10
of 3 925
pro vyhledávání: '"F. Hoffmann-La Roche Ltd"'
Autor:
Ellen Paula, Tatiana Matsumoto, M Alves, F. Hoffmann-La Roche Ltd. Analista de Estratégia de Valor, F. Hoffmann-La Roche Ltd. Estagiária de Estratégia de Valor, F. Hoffmann-La Roche Ltd. Gerente de Estratégia de Valor, Camila Rufino
Publikováno v:
Jornal Brasileiro de Economia da Saúde. 8:185-191
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::865fd8743d9c7355a172b09c10d9a41a
https://doi.org/10.21115/jbes.v8.n3.p185-191
https://doi.org/10.21115/jbes.v8.n3.p185-191
Autor:
Camila Rufino, M Alves, Rodrigo Shimabukuro Ho, Claudio Lisondo, Cintia Oliveira, F. Hoffmann-La Roche Ltd.
Publikováno v:
Jornal Brasileiro de Economia da Saúde. 9:89-95
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af64154127249b4e06acf18730c66656
https://doi.org/10.21115/jbes.v9.suppl1.89-95
https://doi.org/10.21115/jbes.v9.suppl1.89-95
Autor:
M Alves, Juliana Marques Lagrasta Biondo, F. Hoffmann-La Roche Ltd., Camila Rufino, Rodrigo Shimabukuro Ho, Carolina Tsuschiya
Publikováno v:
Jornal Brasileiro de Economia da Saúde. 9:41-48
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46887cd17fad4eef92c1a04b03a105f6
https://doi.org/10.21115/jbes.v9.suppl1.41-48
https://doi.org/10.21115/jbes.v9.suppl1.41-48
Autor:
Charles K. Fisher, Aaron M. Smith, Jonathan R. Walsh, Coalition Against Major Diseases, Abbott, Alliance for Aging Research, Alzheimer’s Association, Alzheimer’s Foundation of America, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Critical Path Institute, CHDI Foundation, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Forest Research Institute, Genentech, Inc., GlaxoSmithKline, Johnson & Johnson, National Health Council, Novartis Pharmaceuticals Corporation, Parkinson’s Action Network, Parkinson’s Disease Foundation, Pfizer, Inc., sanofi-aventis. Collaborating Organizations: Clinical Data Interchange Standards Consortium (CDISC), Ephibian, Metrum Institute.
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-14 (2019)
Scientific Reports
Scientific Reports
Most approaches to machine learning from electronic health data can only predict a single endpoint. The ability to simultaneously simulate dozens of patient characteristics is a crucial step towards personalized medicine for Alzheimer’s Disease. He
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c101fc21a20ed8ce94b12dcb5a5ec42a
https://doi.org/10.1038/s41598-019-49656-2
https://doi.org/10.1038/s41598-019-49656-2
Autor:
Fisher, Charles K, Smith, Aaron M, Walsh, Jonathan R, Coalition Against Major Diseases, Abbott, Alliance for Aging Research, Alzheimer’s Association, Alzheimer’s Foundation of America, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Critical Path Institute, CHDI Foundation, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Forest Research Institute, Genentech, Inc., GlaxoSmithKline, Johnson & Johnson, National Health Council, Novartis Pharmaceuticals Corporation, Parkinson’s Action Network, Parkinson’s Disease Foundation, Pfizer, Inc., sanofi-aventis. Collaborating Organizations: Clinical Data Interchange Standards Consortium (CDISC), Ephibian, Metrum Institute.
Publikováno v:
Scientific reports, vol 9, iss 1
Most approaches to machine learning from electronic health data can only predict a single endpoint. The ability to simultaneously simulate dozens of patient characteristics is a crucial step towards personalized medicine for Alzheimer's Disease. Here
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::b741e1b4d91874089ef97d675f158f16
https://escholarship.org/uc/item/9gr9344s
https://escholarship.org/uc/item/9gr9344s
Autor:
F. Hoffmann-La Roche Ltd, São Paulo, Brazil, Carolina Terumi Tsuchiya, Rui Fernando Weschenfelder, Cintia Sayuri Kurokawa La Scala, Jairo Amorim Simões, Hellen Soo Jin Kim
Publikováno v:
Jornal Brasileiro de Economia da Saúde. 8:24-38
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d52af971d33f872f90b134a7c745b092
https://doi.org/10.21115/jbes.v8.n1.p24-38
https://doi.org/10.21115/jbes.v8.n1.p24-38
Autor:
F. Hoffmann-La Roche Ltd.
Publikováno v:
European Cardiology Review. 1:1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8bac6f019c31db6b8ba958480eec206
https://doi.org/10.15420/ecr.2005.1t
https://doi.org/10.15420/ecr.2005.1t
Autor:
J. Tabernero, F. Andre, J.-Y. Blay, A. Bustillos, S. Fear, S. Ganta, D. Jaeger, M. Maio, L. Mileshkin, I. Melero
Publikováno v:
Scientia
PD-L1 checkpoint inhibitor; Atezolizumab; Solid tumors Inhibidor del punto de control PD-L1; Atezolizumab; Tumores sólidos Inhibidor del punt de control PD-L1; Atezolizumab; Tumors sòlids Background The programmed death-ligand 1 inhibitor atezolizu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::280e1bd6354f6c5c8dc082073f62ec0c
https://pubmed.ncbi.nlm.nih.gov/35305400
https://pubmed.ncbi.nlm.nih.gov/35305400
Publikováno v:
Pharmaceutical Research
Pharmaceutical Research, American Association of Pharmaceutical Scientists, 2017, 34 (10), pp.2109-2118. ⟨10.1007/s11095-017-2216-1⟩
Pharmaceutical Research, American Association of Pharmaceutical Scientists, 2017, 34 (10), pp.2109-2118. ⟨10.1007/s11095-017-2216-1⟩
International audience; PURPOSE:This manuscript aims to precisely describe the natural disease progression of Parkinson's disease (PD) patients and evaluate approaches to increase the drug effect detection power.METHODS:An item response theory (IRT)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb35316ffcb8c6929975ce562193d111
https://www.hal.inserm.fr/inserm-01563224/document
https://www.hal.inserm.fr/inserm-01563224/document